Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 11/20 | 0.41 |
| ▸ | CCNC | P24863 | 4/20 | 0.39 |
| ▸ | CDK8 | P49336 | 4/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30509527 | 0.83 | AXL (0.47) | AXLPRKCIEGFRPIK3CANFATC1 | |
| SCHEMBL21917159 | 0.83 | AXL (0.47) | AXLPRKCIEGFRPIK3CANFATC1 | |
| SCHEMBL277031 | 0.74 | EP300 (0.47) | EGFRCCNCCDK8SLC22A12PIK3CA | |
| SCHEMBL277030 | 0.74 | SLC22A12 (0.42) | EGFRCCNCCDK8SLC22A12PIK3CA | |
| SCHEMBL38657246 | 0.74 | KDM4C (0.40) | AXLEGFRCCNCCDK8SLC22A12 | |
| SCHEMBL3147611 | 0.74 | CCR1 (0.46) | EGFRCCNCCDK8SLC22A12PIK3CA | |
| SCHEMBL3147605 | 0.74 | CCNC (0.39) | EGFRCCNCCDK8SLC22A12PIK3CA | |
| SCHEMBL2008208 | 0.74 | CCNC (0.39) | EGFRCCNCCDK8SLC22A12PIK3CA | |
| SCHEMBL2879912 | 0.74 | NCF1 (0.57) | AXLEGFRCCNCCDK8SLC22A12 | |
| SCHEMBL16247883 | 0.74 | DYRK1A (0.39) | EGFRCCNCCDK8SLC22A12PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1075478-B1 | PHENYLUREA AND PHENYLTHIO UREA DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2003-04-16 | — | — | EP | claimed |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-112088157-B | Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors | 拉文纳制药公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-112088157-A | Aryl-bipyridine amine derivatives as phosphoinositide kinase inhibitors | 拉文纳制药公司 | 2020-12-15 | — | — | CN | disclosed |
| EP-3728230-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20100081650-A1 | Antimicrobial Compounds | AXTEN JEFFREY MICHAEL | 2010-04-01 | — | — | US | disclosed |
| US-7622481-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-1537123-B1 | AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | GLAXO GROUP LTD (GB) | 2009-04-29 | — | — | EP | disclosed |
| US-20060189604-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1537123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004002992-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-01-08 | — | — | WO | disclosed |
| US-4716170-A | 5-[1H-(5-membered-N-aromatic heteryl)-1-yl]-1,6-naphthyridin-2(1H)-ones and their cardiotonic use | STERLING DRUG INC. (US) | 1987-12-29 | — | — | US | disclosed |
| US-4697021-A | 1,6-dihydro-6-oxo-3-pyridinecarbonitriles, intermediates for cardiotonic agents | STERLING DRUG INC. (US) | 1987-09-29 | — | — | US | disclosed |
| US-4657915-A | INOTROPIC AGENTS | STERLING DRUG INC. (US) | 1987-04-14 | — | — | US | disclosed |
| US-4634772-A | 2-[2-(di-lower-alkylamino)-1-propenyl]-6-methoxy-3-pyridinecarbonitriles, intermediates for cardiotonic agents | STERLING DRUG INC. (US) | 1987-01-06 | — | — | US | disclosed |
| EP-0189853-A2 | 1,6-Naphthyridin-2(1H)-ones having cardiotonic activity and preparation | STERLING DRUG INC. (US) | 1986-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1A, PIP5K1B, PIP5K1C | AXL 1942/4885PRKCI 749/4885EGFR 644/4885 |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | AXL 674/4885PRKCI 476/4885EGFR 29/4885 |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PIP5K1C | AXL 1942/4885PRKCI 749/4885EGFR 644/4885 |
| US-20060189604-A1 | Compounds | ELANE, PIGS, SDHA | AXL 4207/4885PRKCI 4509/4885EGFR 2727/4885 |
| US-20100081650-A1 | Antimicrobial Compounds | ELANE, NISCH, PIGS | AXL 4158/4885PRKCI 4447/4885EGFR 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.